These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12185285)

  • 1. Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination.
    Moore RA; Nicholls PK; Santos EB; Gough GW; Stanley MA
    J Gen Virol; 2002 Sep; 83(Pt 9):2299-2301. PubMed ID: 12185285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic immunisation with COPV early genes by epithelial DNA delivery.
    Moore RA; Walcott S; White KL; Anderson DM; Jain S; Lloyd A; Topley P; Thomsen L; Gough GW; Stanley MA
    Virology; 2003 Sep; 314(2):630-5. PubMed ID: 14554090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles.
    Moore RA; Santos EB; Nicholls PK; White KL; Anderson DM; Lloyd A; Topley P; Romanos M; Thomsen L; Parmar V; Walcott S; Gough GW; Stanley MA
    Virology; 2002 Dec; 304(2):451-9. PubMed ID: 12504584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.
    Stanley MA; Moore RA; Nicholls PK; Santos EB; Thomsen L; Parry N; Walcott S; Gough G
    Vaccine; 2001 Apr; 19(20-22):2783-92. PubMed ID: 11282188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-mediated immune responses to COPV early proteins.
    Jain S; Moore RA; Anderson DM; Gough GW; Stanley MA
    Virology; 2006 Dec 5-20; 356(1-2):23-34. PubMed ID: 16949120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.
    Johnston KB; Monteiro JM; Schultz LD; Chen L; Wang F; Ausensi VA; Dell EC; Santos EB; Moore RA; Palker TJ; Stanley MA; Jansen KU
    Virology; 2005 Jun; 336(2):208-18. PubMed ID: 15892962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
    Suzich JA; Ghim SJ; Palmer-Hill FJ; White WI; Tamura JK; Bell JA; Newsome JA; Jenson AB; Schlegel R
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11553-7. PubMed ID: 8524802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
    Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection.
    Nicholls PK; Klaunberg BA; Moore RA; Santos EB; Parry NR; Gough GW; Stanley MA
    Virology; 1999 Dec; 265(2):365-74. PubMed ID: 10600607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
    Yuan H; Estes PA; Chen Y; Newsome J; Olcese VA; Garcea RL; Schlegel R
    J Virol; 2001 Sep; 75(17):7848-53. PubMed ID: 11483728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.
    Ghim S; Newsome J; Bell J; Sundberg JP; Schlegel R; Jenson AB
    Exp Mol Pathol; 2000 Jun; 68(3):147-51. PubMed ID: 10816383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model.
    Bell JA; Sundberg JP; Ghim SJ; Newsome J; Jenson AB; Schlegel R
    Pathobiology; 1994; 62(4):194-8. PubMed ID: 7734063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of canine oral papillomavirus-DNA in canine oral squamous cell carcinomas and p53 overexpressing skin papillomas of the dog using the polymerase chain reaction and non-radioactive in situ hybridization.
    Teifke JP; Löhr CV; Shirasawa H
    Vet Microbiol; 1998 Feb; 60(2-4):119-30. PubMed ID: 9646444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of viral DNA and E4 protein in basal keratinocytes of experimental canine oral papillomavirus lesions.
    Nicholls PK; Doorbar J; Moore RA; Peh W; Anderson DM; Stanley MA
    Virology; 2001 May; 284(1):82-98. PubMed ID: 11352670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of human papillomaviruses in the normal oral cavity of adults.
    Terai M; Hashimoto K; Yoda K; Sata T
    Oral Microbiol Immunol; 1999 Aug; 14(4):201-5. PubMed ID: 10551162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
    Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
    J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of biotechnology to human-papillomavirus-induced diseases.
    Faras AJ; Pass F
    Clin Dermatol; 1985; 3(4):200-3. PubMed ID: 2850858
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular characteristics of cutaneous papillomavirus from the canine pigmented epidermal nevus.
    Tanabe C; Kano R; Nagata M; Nakamura Y; Watanabe S; Hasegawa A
    J Vet Med Sci; 2000 Nov; 62(11):1189-92. PubMed ID: 11129863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloning and characterization of a canine oral papillomavirus.
    Sundberg JP; O'Banion MK; Schmidt-Didier E; Reichmann ME
    Am J Vet Res; 1986 May; 47(5):1142-4. PubMed ID: 3013052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.